Clinical Trial Update: Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction [Phase 1, Phase 2]

View source ↗

Summary

A safety and efficacy study of MSB-CAR001 in subjects after ACL reconstruction completed Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Cruciate Ligament Injury
• Osteoarthritis

Drugs mentioned

• MSB-CAR001

Snippet

Sponsor: Mesoblast, Ltd. | Conditions: Anterior Cruciate Ligament Injury, Osteoarthritis | Phase 1, Phase 2 | Status: COMPLETED